Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Ritter Pharmaceuticals Presents at the 10th Annual LD Micro Conference on December 5, 2017


Posted on: 29 Nov 17

LOS ANGELES, Nov. 29, 2017 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today announced that the Company’s president, Andrew Ritter, will present at the 10th Annual LD Micro Conference on Tuesday, December 5, 2017, at 9:00 a.m. PST in Los Angeles.

Andrew Ritter will be available to participate in one-on-one meetings with investors that week. Conference participants who are interested in scheduling a meeting are encouraged to sign up through the conference’s portal, or by calling Shaun Novin at 310-203-1000.

The LD Micro Main Event is the largest independent conference for small / microcap companies and will feature over 200 of the most influential companies in the microcap space. The conference will be held December 5-7, 2017, at the Luxe Sunset Boulevard Hotel, located at: 11461 Sunset Boulevard, Los Angeles.

The Company’s presentation will be available for the public to access at www.ritterpharma.com. View Ritter Pharmaceuticals profile here: https://www.ldmicro.com/profile/RTTR.

About Ritter Pharmaceuticals

Ritter Pharmaceuticals, Inc. (www.RitterPharma.com, @RitterPharma) develops novel therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases. Its lead product, RP‐G28, has the potential to become the first FDA‐approved treatment for lactose intolerance, a condition that affects millions worldwide. The Company is further exploring the functionality and discovering the therapeutic potential gut microbiome changes may have on treating/preventing a variety of conditions including: gastrointestinal diseases, immuno‐oncology, metabolic, and liver disease.

Forward-Looking Statements

This release may contain forward-looking statements, which express the current beliefs and expectations of Ritter Pharmaceuticals’ management. Such statements involve a number of known and unknown risks and uncertainties that could cause the Company’s future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Any statements contained herein that do not describe historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements. These forward-looking statements are made only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT: Contacts Investor Contact: Jeffrey Benjamin 310-203-1000 Jeffrey@ritterpharma.comGlobeNewswire
globenewswire.com

Last updated on: 30/11/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.